TheRapeutic StrAtegies for Obstructive SleeP Apnea in Older Adults with OverweigHt or Obesity: A RandomizEd Clinical TriaL (RAPHAEL study)

Status

Not yet recruiting

Phases

Phase 4

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2025-524819-37-00

Enrollment

345

Registered

2026-03-30

Start date

Unknown

Completion date

Unknown

Last updated

2026-03-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

obstructive sleep apnea

Brief summary

The change in Apnea–Hypopnea Index (AHI) at 6 months

Detailed description

OSA pathophysiology (hypoxic burden, delta heart rate, loop gain)., Symptoms (daytime sleepiness)., Blood pressure., Functional and psychological domains (quality of life, sleep quality, circadian rest-activity rhythm, cognitive function, mental health)., Body weight., Molecular mechanisms (biomarkers of inflammation, oxidative stress, obesity, and cardiovascular risk)., Cost-effectiveness.

Interventions

DRUGWegovy 2.4 mg solution for injection in pre-filled pen

Eligibility

Sex/Gender

All

Age

65 Years to No maximum

Design outcomes

Primary

Measure	Time frame
The change in Apnea–Hypopnea Index (AHI) at 6 months	—

Secondary

Measure	Time frame
OSA pathophysiology (hypoxic burden, delta heart rate, loop gain)., Symptoms (daytime sleepiness)., Blood pressure., Functional and psychological domains (quality of life, sleep quality, circadian rest-activity rhythm, cognitive function, mental health)., Body weight., Molecular mechanisms (biomarkers of inflammation, oxidative stress, obesity, and cardiovascular risk)., Cost-effectiveness.	—

Outcome results

None listed

Source: EU CTIS · Data processed: Mar 31, 2026